The original rise of Viagra presented a massive chance for shareholders , but its patent has ended, creating a challenging landscape. Generic versions have flooded the space , eroding profits and putting a squeeze on profit margins . While leading healthcare companies maintain a stake in this area, the future seems unclear by ongoing competition an